Related Experiment Video
Updated: Dec 5, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[How to anticoagulate elderly and fragile patients?]
Joerg Herold1, Rupert Bauersachs1
1Klinikum Darmstadt, Klinik für Gefäßmedizin-Angiologie.
Direct oral anticoagulants (DOACs) show superiority in elderly and frail patients, reducing thrombosis and bleeding risks. This review details their effective use in this challenging population.
Area of Science:
- Cardiovascular Medicine
- Geriatric Medicine
- Pharmacology
Background:
- Increasing age is associated with higher risks of thrombosis, bleeding, and renal impairment.
- Managing anticoagulation in fragile patients (e.g., >75 years, low creatinine clearance, low body weight) presents significant clinical challenges.
- Direct oral anticoagulants (DOACs) are increasingly used for anticoagulation.
Purpose of the Study:
- To summarize new insights into the efficacy and safety of DOACs in fragile patients.
- To describe optimal anticoagulation strategies for this high-risk group.
- To address the challenges of using DOACs in elderly and frail individuals.
Main Methods:
- Review of new registry data.
- Analysis of subgroup data from landmark studies.
- Synthesis of current evidence on DOACs in fragile populations.
Main Results:
- Emerging data suggest DOACs are superior to other anticoagulants in fragile patients.
- DOACs demonstrate a favorable risk-benefit profile in this population.
- Registry analyses provide valuable insights into real-world DOAC use.
Conclusions:
- DOACs represent a safe and effective option for anticoagulation in fragile patients.
- Evidence supports the use of DOACs in elderly patients with comorbidities.
- This article provides guidance on anticoagulation pathways for frail individuals.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

